—
C+
C+ The full Closelook — membership. Open the C+ overview

Veracyte Inc (VCYT) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Veracyte Inc

VCYT in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Veracyte runs genomic diagnostic tests that help doctors decide on treatment for thyroid, prostate, bladder, breast and lung conditions, reading tissue and nasal-swab samples through its own sequencing and analysis platforms. It also supplies instrument services built on the nCounter analysis system. The company is based in South San Francisco and sells its tests to clinicians in the United States and abroad.
Where it sits in the stack
Veracyte carries no seat in our index, so it sits outside the AI build-out stack; within our universe it belongs to the Diagnostics & Research sleeve of the Healthcare sector.
Who it is priced against
No peer group is recorded for Veracyte in the diary; the name the market most often sets alongside it is Exact Sciences, another genomic diagnostics company.
Why Closelook tracks it
Veracyte holds no index seat and carries no Closelook score yet, and it has not appeared in any of the diary's quoted editions so far.
What the diary watches
The diary watches whether Veracyte's recent share weakness, which our chart note shows running below both its short- and long-term averages, steadies or extends as its test volumes move through reimbursement decisions.

Veracyte Inc (VCYT) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for VCYT, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Diagnostics & Research · US · 8 names with week and year-to-date

Peer group

Diagnostics & Research · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against VCYT on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Veracyte Inc (VCYT)?

Veracyte Inc trades as VCYT on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is VCYT in a Closelook index?

Not currently — Veracyte Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does VCYT trade against its moving averages?

Mixed moving-average stack: Trades -15.4% vs the 50-day and -4.6% vs the 200-day average, 33.4% below the 52-week high and +37.7% off the 52-week low; a golden cross printed 72 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Veracyte Inc do?

Veracyte runs genomic diagnostic tests that help doctors decide on treatment for thyroid, prostate, bladder, breast and lung conditions, reading tissue and nasal-swab samples through its own sequencing and analysis platforms. It also supplies instrument services built on the nCounter analysis system. The company is based in South San Francisco and sells its tests to clinicians in the United States and abroad. No peer group is recorded for Veracyte in the diary; the name the market most often sets alongside it is Exact Sciences, another genomic diagnostics company.

Where does Veracyte Inc sit in the AI build-out?

Veracyte carries no seat in our index, so it sits outside the AI build-out stack; within our universe it belongs to the Diagnostics & Research sleeve of the Healthcare sector. Veracyte holds no index seat and carries no Closelook score yet, and it has not appeared in any of the diary's quoted editions so far.

What does this page show?

A live price chart with SMA overlays and drawing tools for VCYT, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Diagnostics & Research. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.